Sorafenib, used for the treatment of HCC, inhibits serin/threonine kinases such as BRAF, CRAF BRAF V600E and ERK1/2, while alectinib was developed to treat anaplastic lymphoma kinase (ALK)-positive NSCLC. Here, BRAF is linked to non-small cell lung carcinoma.